Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.

Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.

BACKGROUND:Antiangiogenic therapies for glioblastoma (GBM) such as bevacizumab (BVZ), have been unable to extend survival in large patient cohorts. However, a subset of patients having angiogenesis-dependent tumors might benefit from these therapies. Currently, there are no biomarkers allowing to di...

Full description

Bibliographic Details
Main Authors: David Molina, Julián Pérez-Beteta, Alicia Martínez-González, Juan M Sepúlveda, Sergi Peralta, Miguel J Gil-Gil, Gaspar Reynes, Ana Herrero, Ramón De Las Peñas, Raquel Luque, Jaume Capellades, Carmen Balaña, Víctor M Pérez-García
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4996463?pdf=render

Internet

http://europepmc.org/articles/PMC4996463?pdf=render

Similar Items